GlassScriptPhysician profile
Christina Perkins
NPI 1265924807
$14,378.69
in general payments reported to CMS, 2019-2025
31 companies · $3,821 in 2025
The $3,821 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,728 · 2022: $2,449 · 2023: $3,085 · 2024: $3,296 · 2025: $3,821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,885 · Education: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,884.68 |
| Education | $316.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,488.86 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,953.82 | 2021-2025 | |
| Janssen Biotech, INC. | $1,501.13 | 2021-2025 | Tremfya, Simponi, Stelara |
| Ucb, INC. | $1,329.79 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $726.67 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Incyte Corporation | $692.06 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $670.35 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $635.32 | 2022-2025 | Sotyktu, Abecma |
| Regeneron Healthcare Solutions, INC. | $633.00 | 2021-2025 | Dupixent |
| Mayne Pharma Commercial LLC | $534.67 | 2021-2025 | |
| Leo Pharma INC. | $513.57 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $429.59 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $397.39 | 2024-2025 | Acthar |
| Galderma Laboratories, L.P. | $310.55 | 2021-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $273.04 | 2023-2025 | Zoryve |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $255.97 | 2021-2025 | Klisyri, Seysara |
| Genzyme Corporation | $196.97 | 2025 | |
| Dermavant Sciences, INC. | $154.57 | 2023-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $133.68 | 2021 | |
| Biofrontera INC. | $101.23 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $83.89 | 2025 | Vtama |
| Hill Dermaceuticals, INC. | $76.53 | 2022-2024 | Tolak |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $71.94 | 2021-2024 | Cabtreo, Arazlo |
| Amgen INC. | $70.37 | 2022-2023 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.39 | 2025 | Spevigo |
| Convatec INC. | $27.65 | 2024 | |
| Tempus Ai, INC | $19.43 | 2024 | |
| Journey Medical Corporation | $15.39 | 2021 | |
| Botanix Sb INC | $14.86 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 | |
| Misonix INC | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.